|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McCracken M, Olsen M, Chen MS Jr, et al:
Cancer incidence, mortality, and associated risk factors among
Asian Americans of Chinese, Filipino, Vietnamese, Korean, and
Japanese ethnicities. CA Cancer J Clin. 57:190–205. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tempero MA, Behrman S, Ben-Josef E, et al:
Pancreatic adenocarcinoma: Clinical practice guidelines in
oncology. J Natl Compr Canc Netw. 3:598–626. 2005.PubMed/NCBI
|
|
5
|
Oettle H, Post S, Neuhaus P, et al:
Adjuvant chemotherapy with gemcitabine vs observation in patients
undergoing curative- intent resection of pancreatic cancer: A
randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Reni M, Cordio S, Milandri C, et al:
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and
gemcitabine in advanced pancreatic cancer: A randomised controlled
multicentre phase III trial. Lancet Oncol. 6:369–376. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Louvet C, Labianca R, Hammel P, et al:
Gemcitabine in combination with oxaliplatin compared with
gemcitabine alone in locally advanced or metastatic pancreatic
cancer: Results of a GERCOR and GISCAD phase III trial. J Clin
Oncol. 23:3509–3516. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rocha Lima CM, Savarese D, Bruckner H, et
al: Irinotecan plus gemcitabine induces both radiographic and CA
19- 9 tumor marker responses in patients with previously untreated
advanced pancreatic cancer. J Clin Oncol. 20:1182–1191. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Heinemann V, Quietzsch D, Gieseler F, et
al: Randomized phase III trial of gemcitabine plus cisplatin
compared with gemcitabine alone in advanced pancreatic cancer. J
Clin Oncol. 24:3946–3952. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Burtness B, Thomas L, Sipples R, et al:
Phase II trial of weekly docetaxel/irinotecan combination in
advanced pancreatic cancer. Cancer J. 13:257–262. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Su YT, Chang HL, Shyue SK and Hsu SL:
Emodin induces apoptosis in human lung adenocarcinoma cells through
a reactive oxygen species- dependent mitochondrial signaling
pathway. Biochem Pharmacol. 70:229–241. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin SY, Lai WW, Ho CC, et al: Emodin
induces apoptosis of human tongue squamous cancer SCC- 4 cells
through reactive oxygen species and mitochondria- dependent
pathways. Anticancer Res. 29:327–335. 2009.PubMed/NCBI
|
|
13
|
Guo Q, Chen Y, Zhang B, Kang M, Xie Q and
Wu Y: Potentiation of the effect of gemcitabine by emodin in
pancreatic cancer is associated with survivin inhibition. Biochem
Pharmacol. 77:1674–1683. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin SZ, Wei WT, Chen H, Chen KJ, Tong HF,
Wang ZH, Ni ZL, Liu HB, Guo HC and Liu DL: Antitumor activity of
emodin against pancreatic cancer depends on its dual role:
Promotion of apoptosis and suppression of angiogenesis. PLoS One.
7:e421462012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu JX, Zhang JH, Li HH, Lai FJ, Chen KJ,
Chen H, Luo J, Guo HC, Wang ZH and Lin SZ: Emodin induces Panc- 1
cell apoptosis via declining the mitochondrial membrane potential.
Oncol Rep. 28:1991–1996. 2012.PubMed/NCBI
|
|
16
|
Weidner N: Current pathologic methods for
measuring intra-tumoral microvessel density within breast carcinoma
and other solid tumors. Breast Cancer Res Treat. 36:169–180. 1995.
View Article : Google Scholar
|
|
17
|
Kato H, Ishikura H, Kawarada Y, Furuya M,
Kondo S, Kato H and Yoshiki T: Anti- angiogenic treatment for
peritoneal dissemination of pancreas adenocarcinoma: A study using
TNP- 470. Jpn J Cancer Res. 92:67–73. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Folkman J: Fundamental concepts of the
angiogenic process. Curr Mol Med. 3:643–651. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Holash J, Maisonpierre PC, Compton D, et
al: Vessel cooption, regression, and growth in tumors mediated by
angiopoietins and VEGF. Science. 284:1994–1998. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kaneshiro T, Morioka T, Inamine M, Kinjo
T, Arakaki J, Chiba I, Sunagawa N, Suzui M and Yoshimi N:
Anthraquinone derivative emodin inhibits tumor- associated
angiogenesis through inhibition of extracellular signal- regulated
kinase 1/2 phosphorylation. Eur J Pharmacol. 553:46–53. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kimura Y, Sumiyoshi M, Taniguchi M and
Baba K: Antitumor and antimetastatic actions of anthrone- C-
glucoside, cassialoin isolated from Cassia garrettiana heartwood in
colon 26- bearing mice. Cancer Sci. 99:2336–2348. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mansour KA, Fritz RC, Jacobs DM and
Vellios F: Pedunculated liposarcoma of the esophagus: A first case
report. J Thorac Cardiovasc Surg. 86:447–450. 1983.PubMed/NCBI
|
|
24
|
Itoh S and ten Dijke P: Negative
regulation of TGF-beta receptor/Smad signal transduction. Curr Opin
Cell Biol. 19:176–184. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Moustakas A and Heldin CH: Signaling
networks guiding epithelial- mesenchymal transitions during
embryogenesis and cancer progression. Cancer Sci. 98:1512–1520.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kang SH, Bang YJ, Im YH, et al:
Transcriptional repression of the transforming growth factor- beta
type I receptor gene by DNA methylation results in the development
of TGF- beta resistance in human gastric cancer. Oncogene.
18:7280–7286. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Miyazono K: TGF- beta/SMAD signaling and
its involvement in tumor progression. Biol Pharm Bull.
23:1125–1130. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jaffee EM, Hruban RH, Canto M and Kern SE:
Focus on pancreas cancer. Cancer Cell. 2:25–28. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Padua D, Zhang XH, Wang Q, Nadal C, Gerald
WL, Gomis RR and Massagué J: TGFbeta primes breast tumors for lung
metastasis seeding through angiopoietin- like 4. Cell. 133:66–77.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Peters BA, Diaz LA, Polyak K, et al:
Contribution of bone marrow- derived endothelial cells to human
tumor vasculature. Nat Med. 11:261–262. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Iorio MV, Ferracin M, Liu CG, et al:
MicroRNA gene expression deregulation in human breast cancer.
Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yanaihara N, Caplen N, Bowman E, Seike M,
Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et
al: Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner
MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ and Schmittgen
TD: Expression profiling identifies microRNA signature in
pancreatic cancer. Int J Cancer. 120:1046–1054. 2007. View Article : Google Scholar
|
|
34
|
Juan D, Alexe G, Antes T, Liu H,
Madabhushi A, Delisi C, Ganesan S, Bhanot G and Liou LS:
Identification of a microRNA panel for clear- cell kidney cancer.
Urology. 75:835–841. 2010. View Article : Google Scholar
|
